期刊文献+

2005—2009年东莞市东华医院抗糖尿病药使用情况分析 被引量:3

Utilization of Antidiabetic Drugs from 2005 to 2009 in Donghua Hospital of Dongguan
下载PDF
导出
摘要 目的:分析东莞市东华医院2005—2009年抗糖尿病药的使用情况及用药趋势。方法:用金额排序法及DDD分析法统计5年来抗糖尿病药在我院的消耗情况、品种分布及用药费用,作为分析判断药物使用情况指标,分析临床糖尿病患者的用药状况。结果:近5年来,我院抗糖尿病药用药金额和用药频率(用药/人次)均有大幅度的增长(口服及注射剂用药金额增幅分别为132.04%和144.46%,且用药频率增幅分别为126.40%和144.46%)。用药金额排序前3位为α-糖苷酶抑制剂、磺酰脲类和双胍类;用药频率(用药/人次)排序前3位为α-糖苷酶抑制剂、磺酰脲类和促进胰岛素分泌剂,阿卡波糖使用最多且同步性好。胰岛素使用均在20%以下,以短效胰岛素使用为主。结论:5年间糖尿病患者口服抗糖尿病药使用较多,其中α-糖苷酶抑制剂的使用占主导地位,胰岛素使用有待提高。 OBJECTIVE:To evaluate the utilization of antidiabetic drugs in our hospital from 2005 to 2009.METHODS:With the method of ordering of consumption sum and analysis on DDDs,the utilization of antidiabetic drugs from 2005 to 2009 in our hospital was analyzed in respect of consumption,categories of drugs and drug costs.RESULTS:From 2005 to 2009 in our hospital,the consumption sum and DDDs of antidiabetic drugs witnessed a sharp increase,up 132.04% for oral antidiabetic drugs and 144.46% for injections of antidiabetic drugs in terms of consumption sum,and up 126.40% for oral antidiabetic drugs and 144.46%(injections) in terms of DDDs.Leading the first 3 places in terms of consumption sum were α-glucosidase inhibitors,Sulfonylurea and Metformin respectively;leading the first 3 places in terms of DDDs were α-glucosidase inhibitors,Sulfonylurea and insulin secretion promoting agents,with Acarbose taking the lead in consumption and which showed a good synchronism.The use of insulin accounted for lower than 20%,in which,the type with short-term efficacy took the lead.CONCLUSION:Over the five years,the consumption of oral antidiabetic drugs was on the high side,much as in the consumption of αglucosidase inhibitors,thus the rational use level of the insulin remains to be elevated
机构地区 东莞市东华医院
出处 《中国医院用药评价与分析》 2010年第11期1001-1003,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 抗糖尿病药 药物使用分析 限定日剂量 Antidiabetic drug Drug utilization analysis Defined daily dose
  • 相关文献

参考文献4

二级参考文献12

共引文献26

同被引文献20

  • 1邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量:1426
  • 2刘维.新型口服降糖药和胰岛素类似物在糖尿病治疗中的地位[J].国际内分泌代谢杂志,2007,27(1):70-72. 被引量:24
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2005, 3: CD002966.
  • 5Xu DY, Zhao SP, Huang QX, et al. Effects of glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2010, 88(1): 71-75.
  • 6Kendall DM, Cuddihy R_M, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use[J]. Eur J Intern Med, 2009, 20(Suppl 2): $329-$339.
  • 7国家药典委员会.中华人民共和国药典·临床用药须知:化学药与生物制品卷[S]北京:中国医药科技出版社,2010573-596.
  • 8陈新谦;金有豫;汤光.新编药物学[M]北京:人民卫生出版社,2003609-619.
  • 92007年版中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2008,24(2). 被引量:269
  • 10莫灼康,杨晓东.2006-2008年我院抗糖尿病药物临床应用分析[J].国际医药卫生导报,2009,15(21):74-76. 被引量:3

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部